BIOATLA INC. - COMMON STOCK

BioAtla Announces Change in Executive Leadership

27 фев 2023 08:07:17 Источник Nasdaq GlobeNewswire

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma

23 фев 2023 08:00:01 Источник Nasdaq GlobeNewswire

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

10 янв 2023 08:00:02 Источник Nasdaq GlobeNewswire

BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference

22 дек 2022 08:00:01 Источник Nasdaq GlobeNewswire

BioAtla to Participate in the Jefferies London Healthcare Conference

08 ноя 2022 08:00:03 Источник Nasdaq GlobeNewswire

BioAtla Announces $65 Million Underwritten Offering of its Common Stock

04 ноя 2022 09:08:20 Источник Nasdaq GlobeNewswire

BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

03 ноя 2022 16:01:01 Источник Nasdaq GlobeNewswire

BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022

27 окт 2022 08:00:02 Источник Nasdaq GlobeNewswire

BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress

09 авг 2022 16:05:01 Источник Nasdaq GlobeNewswire

BioAtla to Participate in the 2022 BTIG Biotechnology Conference

03 авг 2022 08:00:01 Источник Nasdaq GlobeNewswire

BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022

02 авг 2022 08:00:03 Источник Nasdaq GlobeNewswire

BioAtla to Participate in 2022 Jefferies Global Healthcare Conference

01 июн 2022 16:05:00 Источник Nasdaq GlobeNewswire

BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress

04 май 2022 16:01:01 Источник Nasdaq GlobeNewswire

BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022

08 апр 2022 08:00:00 Источник Nasdaq GlobeNewswire